Search Results - "LUPO, Sergio H"

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial by POZNIAK, Anton L, MORALES-RAMIREZ, Javier, BOVEN, Katia, KATABIRA, Elly, STEYN, Dewald, LUPO, Sergio H, SANTOSCOY, Mario, GRINSZTEJN, Beatriz, RUXRUNGTHAM, Kiat, RIMSKY, Laurence T, VANVEGGEL, Simon

“…TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase…”
Get full text

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial by Wilkin, Aimee, Pozniak, Anton L, Morales-Ramirez, Javier, Lupo, Sergio H, Santoscoy, Mario, Grinsztejn, Beatriz, Ruxrungtham, Kiat, Rimsky, Laurence T, Vanveggel, Simon, Boven, Katia

“…TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected,…”
Get more information

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study by Tavel, Jorge A, Babiker, Abdel, Fox, Lawrence, Gey, Daniela, Lopardo, Gustavo, Markowitz, Norman, Paton, Nicholas, Wentworth, Deborah, Wyman, Nicole

“…The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral…”
Get full text